Private equity firms are aggressively targeting the active pharmaceutical ingredients (API) sector, with Astorg, EQT, TA Associates, and New Mountain Capital all making strategic investments. The fragmented market offers resilient demand and long-term structural drivers including biotech-based ingredients, natural solutions, and expanding oncology and rare disease products.

Astorg recently acquired a majority stake in Solabia, a Paris-based biotechnology ingredients provider, from TA Associates. The firm plans to accelerate consolidation through targeted acquisitions that strengthen scientific capabilities and expand global reach. Meanwhile, American Securities is selling two medical components manufacturers - MW Components and CPM Holdings - in a combined $3.25 billion deal expected to close in Q2 2026.

Beyond API investments, private equity is finding opportunities in medical components manufacturing as outsourcing to contract development organizations increases. The sector benefits from steady healthcare spending, material science innovations, and demand for precision-engineered components across medical, aviation, and electronics industries. Life sciences IPO activity is also accelerating in 2026, with six companies already going public as investors grow comfortable with regulatory uncertainty and interest rate environments.